Efficacy and Safety Study of SUNPG1622

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.

Inclusion Criteria:

• Subject has provided informed written consent
• Subject is ≥ 18 years of age at time of Screening
• Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of investigational product
• Subject has a negative test for TB within 4 weeks before initiating IMP

Exclusion Criteria:

• Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes
• Active uveitis or symptomatic inflammatory bowel disease requiring therapy at screening
• Radiographic evidence of total ankylosis of the spine
• Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pre-treatment condition